Serum sclerostin increases in healthy adult men during bed rest

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 9, 2012, Pages

  Spatz, Jordan M ^a,b,d   Fields, E E ^e   Yu, E W ^d   Divieti Pajevic, P ^d   Bouxsein, M L ^a,d   Sibonga, J D ^c   Zwart, S R ^f   Smith, S M ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c NASA JOHNSON SPACE CENTER   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e Enterprise Advisory Services Inc   (United States)

^f UNIVERSITIES SPACE RESEARCH ASSOCIATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; PARATHYROID HORMONE; PHOSPHORUS; SCLEROSTIN; VITAMIN D;

ADULT; ARTICLE; BED REST; BLOOD SAMPLING; BONE DENSITY; BONE TURNOVER; CALCIUM URINE LEVEL; ENZYME ACTIVITY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; OSTEOLYSIS; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE EXCRETION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; URINALYSIS; VITAMIN BLOOD LEVEL;

ABSORPTIOMETRY, PHOTON; ADULT; BED REST; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; BONE MORPHOGENETIC PROTEINS; BONE RESORPTION; CALCIUM; GENETIC MARKERS; HEAD-DOWN TILT; HUMANS; LONGITUDINAL STUDIES; MALE; PARATHYROID HORMONE; PHOSPHORUS; PHYSICAL FITNESS; VITAMIN D;

ANIMALIA;

EID: 84866174959     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-1579     Document Type: Article

References (19)

1. Zwart SR, Crawford GE, Gillman PL, Kala G, Rodgers AS, Rogers A, Inniss AM, Rice BL, Ericson K, Coburn S, Bourbeau Y, Hudson E, Mathew G, Dekerlegand DE, Sams CF, Heer MA, Paloski WH, Smith SM 2009 Effects of 21 days of bed rest, with or without artificial gravity, on nutritional status of humans. J Appl Physiol 107:54-62
2. Zwart SR, Oliver SA, Fesperman JV, Kala G, Krauhs J, Ericson K, Smith SM 2009 Nutritional status assessment before, during, and after long-duration head-down bed rest. Aviat Space Environ Med 80(5 Suppl):A15-A22
3. Inniss AM, Rice BL, Smith SM 2009 Dietary support of long-duration head-down bed rest. Aviat Space Environ Med 80(5 Suppl):A9-A14
4. Gaudio A, Pennisi P, Bratengeier C, Torrisi V, Lindner B, Mangiafico RA, Pulvirenti I, Hawa G, Tringali G, Fiore CE 2010 Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss. J Clin Endocrinol Metab 95:2248-2253
5. Spector ER, Smith SM, Sibonga JD 2009 Skeletal effects of long-duration head-down bed rest. Aviat Space Environ Med 80(5 Suppl):A23-A28
6. Morse LR, Sudhakar S, Danilack V, Tun C, Lazzari A, Gagnon DR, Garshick E, Battaglino RA 2012 Association between sclerostin and bone density in chronic spinal cord injury. J Bone Miner Res 27:352-359
7. LeBlanc AD, Spector ER, Evans HJ, Sibonga JD 2007 Skeletal responses to space flight and the bed rest analog: a review. J Musculoskelet Neuronal Interact 7:33-47 (Pubitemid 46730302)
8. Nakashima T, Hayashi M, Fukunaga T, Kurata K, Oh-Hora M, Feng JQ, Bonewald LF, Kodama T, Wutz A, Wagner EF, Penninger JM, Takayanagi H 2011 Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med 17:1231-1234
9. Xiong J, Onal M, Jilka RL, Weinstein RS, Manolagas SC, O'Brien CA 2011 Matrix-embedded cells control osteoclast formation. Nat Med 17:1235-1241
10. Balemans W, Patel N, Ebeling M, Van Hul E, Wuyts W, Lacza C, Dioszegi M, Dikkers FG, Hildering P, Willems PJ, Verheij JB, Lind-paintner K, Vickery B, Foernzler D, Van Hul W 2002 Identification of a 52 kb deletion downstream of the SOST gene in patients with Van Buchem disease. J Med Genet 39:91-97 (Pubitemid 34146376)
11. van Bezooijen RL, ten Dijke P, Papapoulos SE, Löwik CW 2005 SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev 16:319-327 (Pubitemid 40910321)
12. Semënov M, Tamai K, He X 2005 SOST is a ligand for LRP5/LRP6 and a wnt signaling inhibitor. J Biol Chem 280:26770-26775
13. Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, Shpektor D, Jonas M, Kovacevich BR, Staehling-Hampton K, Appleby M, Brunkow ME, Latham JA 2003 Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 22:6267-6276 (Pubitemid 37522584)
14. Lin C, Jiang X, Dai Z, Guo X, Weng T, Wang J, Li Y, Feng G, Gao X, He L 2009 Sclerostin mediates bone response to mechanical unloading through antagonizing wnt/β-catenin signaling. J Bone Miner Res 24:1651-1661
15. Robling AG, Niziolek PJ, Baldridge LA, Condon KW, Allen MR, Alam I, Mantila SM, Gluhak-Heinrich J, Bellido TM, Harris SE, Turner CH 2008 Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem 283:5866-5875
16. O'Brien CA, Plotkin LI, Galli C, Goellner JJ, Gortazar AR, Allen MR, Robling AG, Bouxsein M, Schipani E, Turner CH, Jilka RL, Weinstein RS, Manolagas SC, Bellido T 2008 Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS One 3:e2942
17. Costa AG, Cremers S, Rubin MR, McMahon DJ, Sliney Jr J, Lazaretti-Castro M, Silverberg SJ, Bilezikian JP 2011 Circulating sclerostin in disorders of parathyroid gland function. J Clin Endocrinol Metab 96:3804-3810
18. Yu EW, Kumbhani R, Siwila-Sackman E, Leder BZ 2011 Acute decline in serum sclerostin in response to PTH infusion in healthy men. J Clin Endocrinol Metab 96:E1848-E1851
19. Drake MT, Srinivasan B, Mödder UI, Peterson JM, McCready LK, Riggs BL, Dwyer D, Stolina M, Kostenuik P, Khosla S 2010 Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab 95:5056-5062